查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929506

信息素市场：按类型、来源、剂型、应用和最终用户划分，全球预测，2026-2032年

Kairomones Market by Type, Source, Formulation, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，费洛蒙市场价值为 3.1084 亿美元，预计到 2026 年将成长至 3.4449 亿美元，预计到 2032 年将达到 6.4537 亿美元，复合年增长率为 11.00%。

关键市场统计数据
基准年 2025 3.1084亿美元
预计年份：2026年 3.4449亿美元
预测年份 2032 6.4537亿美元
复合年增长率 (%) 11.00%

本书对信息素进行了清晰而引人入胜的介绍，阐述了信息素的跨学科重要性、科学基础及其在应用生命科学中的实际意义。

信息素是由一个物种释放的化学讯号，能够影响其他物种的行为和生理。它们独特地融合了生态学、化学和应用生命科学。这些物种间讯号的研究已经从传统的行为测试发展到先进的分子表征和感测器开发，其重要性也从学术研究扩展到农业、公共卫生、生物技术和环境监测等领域的实际应用。

技术、监管和商业化的变革性变化正在推动资讯素应用领域的加速实用化和跨学科发展机会。

随着技术、监管和市场动态的整合并重塑优先事项，资讯素科学和实用化领域正经历着变革性的转变。在技​​术方面，合成生物学和精准胜肽合成显着降低了非挥发性和挥发性化合物的设计和製造门槛，而感测器技术和机器学习的进步则提高了检测灵敏度和生态学解读能力。这些进展正在加速将发现转化为实用产品，并催生出诸如气雾剂给药、封装溶液和缓释製剂等新型给药方式。

分析美国于 2025 年实施的关税对 Kairomone Solutions 的供应链、筹资策略、合作和商业化路径的影响

2025年美国关税政策对从事信息素相关材料和工具的生产、分销和研究的机构产生了一系列营运和战略影响。由于关税改变了进口原材料前驱物、合成胜肽、专用分析设备和製剂成分的经济效益，以往以成本和接近性为优化目标的供应链配置不得不重新评估。传统上依赖国际供应商提供试剂、仪器和客製化合成服务的製造商和实验室，如今面临新的奖励，需要将采购转向国内或实现供应商网路多元化，以降低关税风险并减少前置作业时间波动。

透过全面的細項分析，突显应用、最终用户、分子类型、原材料来源和製剂形式的差异，从而推动产品设计和商业化策略。

细分市场分析揭示了不同应用领域、最终用户、分子类型、生产来源和製剂形式方面的研发路径和优先事项，这些因素共同影响产品设计和市场推广策略。依应用领域划分，研发涵盖动物行为研究、环境监测、害虫防治、药物开发和植物防御研究，而害虫防治又细分为作物保护和城市害虫防治。每种用途对性能、安全性和递送方式都有不同的要求，作物保护解决方案强调环境持久性和靶向释放，而城市害虫防治则优先考虑人身安全和易于实施。

从区域观点比较主要区域的采用趋势、法规要求、研究生态系统和商业化路径

区域特征影响着费洛蒙技术的研究能力、监管严格程度和商业化路径，从而在美洲、欧洲、中东和非洲以及亚太地区创造了独特的机会和挑战。在美洲，强大的私部门创新生态系统和成熟的农业技术应用模式为田间试验和与精密农业平台的整合提供了沃土。法规结构强调安全性和环境评估，该地区的经销网络能够相对快速地扩大配方产品在作物保护和城市害虫防治方面的规模。产学合作也为从发现到应用的转化过程提供了支持。

来自主要企业和合作伙伴的洞见突显了策略趋势、伙伴关係模式和创新重点，这些因素将塑造资讯素生态系统中的竞争优势。

活跃于资讯素领域的主要企业和研究机构构成了一个创新生态系统，其中包括专业公司、大型生命科学公司和进行合作研究的学术机构。一些公司专注于推进胜肽和蛋白质的合成及製剂技术，投资于可扩展的生物加工、稳定化化学以及能够解决保质期和现场耐久性问题的递送系统。另一些公司则专注于挥发性化合物的工程改造，开发缓释基质和感测器整合技术，以实现即时监测和标靶给药。

透过策略伙伴关係和监管准备，加速资讯素技术开发、增强供应链韧性并实现商业化，提出切实可行的建议。

在不断发展的引子素领域，产业领导者可以采取一系列切实可行的措施来加速研发、维持韧性并获得商业性利益。首先，应优先建构模组化的合成和製剂能力，以实现从实验室发现到可应用于实际应用的原型产品的快速迭代。投资于能够稳定胜肽段并实现持续挥发性物质释放的平台技术，将缩短产品验证时间并增强终端用户的信心。其次，应发展多元化的供应商网络，并探索区域性製造地，以降低关税和物流风险，同时在符合永续性和监管目标的前提下，寻求微生物发酵和植物萃取等在地采购方式。

我们采用透明、严谨的调查方法，结合专家访谈、科学综合和分析框架，检验整个资讯素价值链的研究结果。

本分析的调查方法结合了初步定性研究、二次科学技术综合分析以及领域专家的严格交叉检验，以确保其稳健性和相关性。初步调查方法包括对研究人员、产品开发人员和监管专家进行结构化访谈，以收集有关药物发现流程、製剂开发挑战和核准流程的第一手资料。这些定性见解与最新科学文献、专利申请和技术资讯披露的系统性回顾相结合，以绘製非挥发性胜肽和蛋白质以及挥发性氮硫化合物的技术能力图谱。

简明扼要的结论总结了将信息素科学转化为实际成果所需的策略意义、优先行动和协作方法。

本报告的综合分析表明，随着科学技术、製剂研发和递送能力的融合，满足了对靶向、永续解决方案的迫切需求，信息素正处于广泛商业性应用的风口浪尖。其关键意义在于：需要製定一项将稳健的药物发现、实用的製剂技术和监管准备相结合的开发策略；同时，建立能够应对贸易和物流不确定性的灵活供应链也至关重要。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 费洛蒙市场类型

  • 非挥发性
    • 胜肽
    • 蛋白质
  • 易挥发的
    • 氮挥发物
    • 硫挥发物

第九章 费洛蒙市场（依来源划分）

  • 自然的
    • 动物源性
    • 微生物来源
    • 植物来源
  • 合成
    • 生物技术
    • 化学合成

第十章 按配方分類的费洛蒙市场

  • 气体
    • 气雾剂
    • 蒸气
  • 液体
    • 乳液
    • 解决方案
  • 固体的
    • 颗粒
    • 粉末

第十一章 按应用分類的费洛蒙市场

  • 动物行为调查
  • 环境监测
  • 害虫防治
    • 作物保护
    • 城市害虫防治
  • 製药
  • 植物防御调查

第十二章 依最终用户分類的费洛蒙市场

  • 学术和研究机构
    • 研究所
    • 大学
  • 农业
    • 作物保护
    • 畜牧管理
  • 生物技术和製药
    • 生物技术
    • 製药
  • 化妆品

第十三章 区域性费洛蒙市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 集团市场资讯素分析

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国费洛蒙市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国费洛蒙市场

第十七章：中国费洛蒙市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AgriSense-BCS Ltd.
  • Andermatt Biocontrol AG
  • BASF SE
  • Bedoukian Research Inc.
  • Biobest Group NV
  • BioControle
  • Certis USA LLC
  • Hercon Environmental Corporation
  • ISCA Technologies Inc.
  • Koppert Biological Systems
  • Pheromone Chemicals Pvt. Ltd.
  • Russell IPM Ltd.
  • Shin-Etsu Chemical Co. Ltd.
  • Suterra LLC
  • Trece Incorporated
Product Code: MRR-0A38069517E2

The Kairomones Market was valued at USD 310.84 million in 2025 and is projected to grow to USD 344.49 million in 2026, with a CAGR of 11.00%, reaching USD 645.37 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 310.84 million
Estimated Year [2026] USD 344.49 million
Forecast Year [2032] USD 645.37 million
CAGR (%) 11.00%

A clear and compelling introduction to kairomones that defines their interdisciplinary importance, scientific foundations, and practical relevance for applied life sciences

Kairomones are chemical signals emitted by one species that affect the behavior or physiology of another, and they occupy a unique intersection of ecology, chemistry, and applied life sciences. The study of these interspecies cues has matured from classical behavioral assays to sophisticated molecular characterization and sensor development, expanding relevance beyond academic curiosity to practical applications in agriculture, public health, biotechnology, and environmental monitoring.

Contemporary research has deepened understanding of how volatile and non-volatile kairomones modulate predator-prey interactions, influence plant defense responses, and serve as biomarkers for environmental change. Advances in analytical chemistry, such as high-resolution mass spectrometry and targeted peptide sequencing, now allow researchers to isolate and reproduce bioactive compounds with greater precision. Simultaneously, improvements in delivery systems and formulation science enable pragmatic deployment in field settings, whether for crop protection, pest management, or diagnostic assays.

Stakeholders across research institutions, industry, and regulatory bodies increasingly recognize the strategic value of kairomone-based approaches to reduce reliance on broad-spectrum agents, enhance specificity, and support integrated management strategies. This introduction frames the scientific foundations and translational pathways for kairomones, setting the stage for an analysis of the forces reshaping their development, commercialization, and adoption.

Transformative shifts in technology, regulation, and commercialization that are accelerating translation and creating multidisciplinary opportunities across kairomone applications

The landscape for kairomone science and deployment is undergoing transformative shifts driven by technological, regulatory, and market dynamics that are converging to reshape priorities. On the technology front, synthetic biology and precision peptide synthesis have dramatically lowered barriers to designing and producing non-volatile and volatile compounds, while advances in sensor technology and machine learning enhance detection sensitivity and ecological interpretation. These developments accelerate translation from discovery to practical products and enable new modalities such as aerosolized delivery, encapsulated solutions, and controlled-release formulations.

At the same time, sustainability and specificity imperatives are steering end users toward solutions that minimize non-target impacts and integrate with biological control approaches. In agricultural contexts, this has intensified interest in crop protection strategies that rely on plant-derived or microbial-derived sources to modulate pest behavior without escalating chemical inputs. Regulatory regimes are also evolving, with heightened scrutiny on environmental safety and biosecurity prompting developers to prioritize clear safety dossiers, traceable sourcing, and robust environmental fate studies. These requirements are catalyzing closer collaboration between academic and research institutes and industry partners to close data gaps and expedite approvals.

Furthermore, commercialization paradigms are shifting from single-product models toward platform approaches that combine formulation expertise, delivery systems, and data analytics. Firms are increasingly bundling active kairomone compounds with diagnostic sensors or agronomic advisory services that amplify value for end users. Cross-sector partnerships are emerging, linking biotechnology companies with agricultural integrators, pest control providers, and environmental monitoring specialists to leverage complementary strengths. Collectively, these shifts are creating a more sophisticated, multidisciplinary ecosystem in which scientific innovation, application design, and regulatory strategy must be tightly aligned to realize impact.

Analyzing how United States tariff measures introduced in 2025 are influencing supply chains, procurement strategies, collaborative research, and commercialization pathways for kairomone solutions

United States tariff actions in 2025 have introduced a set of operational and strategic reverberations for organizations engaged in the production, distribution, and research of kairomone-related materials and tools. Supply chain configurations that once optimized for cost and proximity now require reassessment as duties alter the comparative economics of importing raw precursors, synthesized peptides, specialized analytical equipment, and formulation components. Manufacturers and research laboratories that previously relied on international suppliers for reagents, instrumentation, or bespoke synthesis services face new incentives to localize procurement or to diversify vendor networks to mitigate tariff exposure and reduce lead-time volatility.

Those shifts have downstream implications for collaborative research and contract manufacturing arrangements. Cross-border collaborations that depend on timely exchange of biological samples or analytical outputs must adapt logistics planning and contractual terms to accommodate increased customs scrutiny and potential delays. Strategic responses include bolstering domestic contract research and manufacturing capacity, renegotiating supply agreements with explicit tariff contingency provisions, and investing in in-house synthesis capabilities for critical non-volatile and volatile compounds. Developers of kairomone-based solutions may also alter their formulation strategies to prioritize components that are less impacted by tariff differentials, including leveraging locally available natural sources such as plant-derived extracts or microbial fermentation products when appropriate.

Financially, organizations need to incorporate tariff scenarios into procurement workflows and supplier evaluation frameworks to maintain margin integrity without compromising product efficacy or regulatory compliance. Research institutions and smaller enterprises in particular should evaluate collaborative purchasing consortia or shared facilities as mechanisms to preserve access to high-cost analytical platforms and specialized reagents. From a policy perspective, ongoing engagement with trade authorities and industry associations will be important to ensure that the regulatory context considers the unique attributes of biologically active compounds and the potential unintended consequences of broad tariff measures on research and environmental management objectives.

Comprehensive segmentation insights illuminating application, end user, molecular type, source, and formulation distinctions that drive product design and commercialization strategies

Segmentation insights reveal distinct pathways and priorities across application domains, end users, molecular types, production sources, and formulation modalities that together shape product design and go-to-market strategies. Based on application, research and product development span animal behavior research, environmental monitoring, pest control, pharmaceutical development, and plant defense research, with pest control bifurcated into crop protection and urban pest control. Each application imposes different performance, safety, and delivery requirements, where solutions tailored to crop protection emphasize environmental persistence and targeted release, while urban pest control prioritizes human safety and ease of deployment.

Considering end users, the landscape contains academic and research institutes, agriculture, biotechnology and pharmaceutical firms, and cosmetics companies, with academic and research institutes further split into research laboratories and universities, agriculture divided into crop protection and livestock management, and biotechnology and pharma differentiated between biotechnology developers and pharmaceutical manufacturers. These distinctions matter because research labs and universities often drive early discovery and fundamental characterization, whereas agriculture and biotechnology firms focus on scaling, formulation, and regulatory pathways suited to field or clinical contexts. Cosmetics end users evaluate kairomone-derived compounds for odor modulation and protective properties under stringent consumer safety frameworks, affecting purity and formulation choices.

From a type perspective, kairomone offerings segregate into non-volatile and volatile classes, where non-volatile compounds further include peptides and proteins and volatile classes encompass nitrogen and sulfur volatiles. The molecular type drives analytical methods, storage needs, and delivery mechanisms; peptides and proteins demand cold chain considerations and protease protection, while volatile compounds require engineering of controlled-release matrices or vapor delivery systems. Source segmentation contrasts natural and synthetic origins, with natural sources further categorized as animal derived, microbial derived, and plant derived, and synthetic sources traced to biotechnology approaches or chemical synthesis. Source selection influences regulatory classification, sustainability narratives, and supply security; microbial fermentation can provide scalable, consistent supply while plant-derived extracts may offer faster regulatory pathways in some jurisdictions but pose variability challenges.

Finally, formulation segmentation spans gas, liquid, and solid formats, where gas formulations break down into aerosol and vapor, liquid formulations include emulsion and solution, and solids are represented by granule and powder forms. Formulation choice links to end-use practicality and environmental behavior: aerosol and vapor formats can enable rapid dispersal for behavioral manipulation, emulsions support foliar application in crop protection, and granules or powders can offer long-term field persistence. Integrating these segmentation lenses allows developers to design products that align with targeted applications and end users, optimize supply chains by selecting appropriate sources and types, and craft regulatory and commercialization strategies that reflect the specific demands of each segment.

Key regional perspectives that contrast adoption dynamics, regulatory expectations, research ecosystems, and commercialization pathways across major global geographies

Regional dynamics shape research capacity, regulatory rigor, and commercialization pathways for kairomone technologies, producing differentiated opportunities and constraints across the Americas, Europe Middle East & Africa, and Asia-Pacific regions. In the Americas, a strong private-sector innovation ecosystem and established agricultural technology adoption patterns create fertile ground for field trials and integration with precision agronomy platforms. Regulatory frameworks emphasize safety and environmental assessment, and the region's distribution networks enable relatively rapid scaling of formulated products for crop protection and urban pest control. Collaborative relationships between academia and industry also support translational pipelines from discovery to application.

In Europe, Middle East & Africa, the regulatory landscape places significant emphasis on environmental protection and precautionary assessment, which raises the bar for ecotoxicology and non-target species evaluations but simultaneously cultivates demand for highly specific, low-impact solutions. The region's diverse agricultural systems and strong research institutions facilitate niche applications and pilot programs, while growing interest in sustainable pest management increases receptivity to plant-derived and microbial-derived solutions. Market access strategies in this region often require comprehensive environmental dossiers and clear sustainability narratives.

The Asia-Pacific region presents a mix of rapid adoption potential and supply chain complexity, with large agricultural markets eager for scalable crop protection innovations and urban centers confronting elevated pest management needs. Manufacturing capacity and contract synthesis capabilities are expanding across several economies, enabling regional production of synthesized peptides and volatile compounds. However, developers must navigate heterogeneous regulatory regimes and local sourcing preferences, which can favor natural or plant-derived approaches in some markets while driving demand for cost-efficient synthetic solutions in others. Understanding these regional distinctions is essential for prioritizing R&D investments, structuring regulatory submissions, and tailoring commercialization strategies to local end-user expectations.

Key company and collaborator insights that highlight strategic moves, partnership models, and innovation priorities shaping competitive dynamics in the kairomone ecosystem

Leading companies and research organizations operating in the kairomone domain demonstrate a mixture of dedicated specialist firms, larger life sciences players, and collaborative academic centers that together form an innovation ecosystem. Some firms have concentrated on refining synthesis and formulation capabilities for peptides and proteins, investing in scalable bioprocessing, stabilization chemistries, and delivery systems that address shelf life and field robustness. Other companies emphasize volatile compound engineering, developing controlled-release matrices and sensor integration to enable real-time monitoring and targeted deployment.

Strategic partnerships are a recurrent theme: commercial entities commonly co-develop products with academic laboratories to access novel bioactivity data, while contract manufacturers and formulation specialists enable rapid scale-up once bioactive compounds are validated. Several organizations have adopted platform approaches, pairing active compounds with diagnostics or data services to create differentiated value propositions for growers, pest control operators, and environmental monitoring agencies. Intellectual property strategies vary, with firms protecting proprietary synthesis routes, formulation technologies, and application methodologies while also leveraging open scientific collaborations to accelerate discovery.

Investment patterns suggest a pragmatic focus on de-risking late-stage development through staged validation, regulatory data generation, and pilot deployments. Companies that succeed tend to integrate scientific rigor with operational capabilities, including regulatory affairs, supply chain resilience, and commercial partnerships that facilitate distribution and field support. For stakeholders considering entry or expansion, aligning organizational competencies with these successful patterns will be critical for converting technological promise into sustainable commercial outcomes.

Actionable recommendations for leaders to accelerate development, strengthen supply resilience, and commercialize kairomone innovations through strategic partnerships and regulatory readiness

Industry leaders can take a set of pragmatic actions to accelerate development, preserve resilience, and capture commercial upside in the evolving kairomone landscape. First, prioritize building modular capabilities for synthesis and formulation that allow rapid iteration between laboratory discovery and field-ready prototypes; investing in platform technologies for peptide stabilization and controlled-release of volatiles will reduce time to demonstration and improve end-user confidence. Second, establish diversified supplier networks and consider regional manufacturing footprints to mitigate tariff and logistics risks, while pursuing local sourcing options such as microbial fermentation or plant extraction where they align with sustainability and regulatory objectives.

Third, deepen collaborative ties with academic and research institutes to secure early access to discovery science and to co-generate the robust safety and environmental data required by regulators. Co-funded pilot trials and shared analytical resources can lower the cost of validation while accelerating evidence generation. Fourth, design commercialization strategies that bundle active compounds with complementary services-such as diagnostic support, agronomic advisory, or data analytics-to increase stickiness and value for end users. This approach also enables premium positioning for solutions that demonstrably reduce non-target impacts and integrate with integrated pest management frameworks.

Finally, adopt adaptive regulatory strategies that anticipate evolving environmental scrutiny by investing early in ecotoxicology, non-target impact studies, and transparent traceability of source materials. Communicate sustainability narratives credibly by validating claims through third-party assessments and standardized testing. By executing these actions with disciplined project management and rigorous data practices, organizations can navigate the complex scientific, regulatory, and commercial terrain more effectively and accelerate the translation of kairomone science into impactful products.

A transparent and rigorous research methodology combining expert interviews, scientific synthesis, and analytical frameworks to validate insights across the kairomone value chain

The research methodology underpinning this analysis integrates primary qualitative inquiry, secondary scientific and technical synthesis, and rigorous cross-validation with domain experts to ensure robustness and relevance. Primary inputs included structured interviews with researchers, product developers, and regulatory specialists to capture first-hand insights into discovery pipelines, formulation challenges, and approval pathways. These qualitative insights were triangulated with a systematic review of contemporary scientific literature, patent filings, and technical disclosures to map technological capabilities across non-volatile peptides and proteins as well as volatile nitrogen and sulfur compounds.

Analytical frameworks focused on value chain mapping, segmentation alignment, and scenario analysis to assess how source, type, application, end user, and formulation choices influence product development and commercialization. Supply chain and procurement considerations were examined through logistics and sourcing lenses, with attention to tariff impacts, manufacturing capacity, and material traceability. Expert validation workshops provided critical checks on interpretation and highlighted emerging priorities such as sensor integration, controlled-release technologies, and regulatory data needs.

This mixed-methods approach prioritized transparency in assumptions and documented sources of evidence for qualitative judgments. Wherever possible, technical claims were grounded in peer-reviewed findings or validated by practitioner testimony. The methodology favors iterative validation cycles to incorporate new data and stakeholder feedback, ensuring the analysis remains current and actionable for decision-makers navigating scientific, operational, and regulatory complexities.

A concise conclusion synthesizing strategic implications, priorities for action, and the coordinated approaches required to translate kairomone science into practical impact

The synthesis presented here underscores that kairomones are at the threshold of broader commercial adoption as scientific capabilities, formulation science, and delivery technologies converge with pressing needs for targeted, sustainable solutions. Key implications include the necessity for integrated development strategies that combine robust discovery with pragmatic formulation and regulatory preparedness, and the importance of flexible supply chains in the face of trade and logistical uncertainties.

Decision-makers should prioritize investments that reduce technical risk-such as scalable synthesis and stabilized formulations-while cultivating partnerships that accelerate evidence generation and field validation. Regional strategies must be calibrated to local regulatory expectations and adoption receptivity, and companies that pair strong science with operational execution will be best positioned to capture emerging opportunities. In sum, the path from laboratory discovery to impactful application requires coordinated action across R&D, supply chain, regulatory affairs, and commercial channels to realize the strategic potential of kairomone-based solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Kairomones Market, by Type

  • 8.1. Non Volatile
    • 8.1.1. Peptides
    • 8.1.2. Proteins
  • 8.2. Volatile
    • 8.2.1. Nitrogen Volatiles
    • 8.2.2. Sulfur Volatiles

9. Kairomones Market, by Source

  • 9.1. Natural
    • 9.1.1. Animal Derived
    • 9.1.2. Microbial Derived
    • 9.1.3. Plant Derived
  • 9.2. Synthetic
    • 9.2.1. Biotechnology
    • 9.2.2. Chemical Synthesis

10. Kairomones Market, by Formulation

  • 10.1. Gas
    • 10.1.1. Aerosol
    • 10.1.2. Vapor
  • 10.2. Liquid
    • 10.2.1. Emulsion
    • 10.2.2. Solution
  • 10.3. Solid
    • 10.3.1. Granule
    • 10.3.2. Powder

11. Kairomones Market, by Application

  • 11.1. Animal Behavior Research
  • 11.2. Environmental Monitoring
  • 11.3. Pest Control
    • 11.3.1. Crop Protection
    • 11.3.2. Urban Pest Control
  • 11.4. Pharmaceutical
  • 11.5. Plant Defense Research

12. Kairomones Market, by End User

  • 12.1. Academic & Research Institutes
    • 12.1.1. Research Laboratories
    • 12.1.2. Universities
  • 12.2. Agriculture
    • 12.2.1. Crop Protection
    • 12.2.2. Livestock Management
  • 12.3. Biotechnology & Pharma
    • 12.3.1. Biotechnology
    • 12.3.2. Pharmaceutical
  • 12.4. Cosmetics

13. Kairomones Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Kairomones Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Kairomones Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Kairomones Market

17. China Kairomones Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AgriSense-BCS Ltd.
  • 18.6. Andermatt Biocontrol AG
  • 18.7. BASF SE
  • 18.8. Bedoukian Research Inc.
  • 18.9. Biobest Group NV
  • 18.10. BioControle
  • 18.11. Certis USA LLC
  • 18.12. Hercon Environmental Corporation
  • 18.13. ISCA Technologies Inc.
  • 18.14. Koppert Biological Systems
  • 18.15. Pheromone Chemicals Pvt. Ltd.
  • 18.16. Russell IPM Ltd.
  • 18.17. Shin-Etsu Chemical Co. Ltd.
  • 18.18. Suterra LLC
  • 18.19. Trece Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL KAIROMONES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL KAIROMONES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL KAIROMONES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL KAIROMONES MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL KAIROMONES MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL KAIROMONES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL KAIROMONES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL KAIROMONES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL KAIROMONES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL KAIROMONES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL KAIROMONES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES KAIROMONES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA KAIROMONES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL KAIROMONES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL KAIROMONES MARKET SIZE, BY NON VOLATILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL KAIROMONES MARKET SIZE, BY NON VOLATILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL KAIROMONES MARKET SIZE, BY NON VOLATILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL KAIROMONES MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL KAIROMONES MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL KAIROMONES MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL KAIROMONES MARKET SIZE, BY PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL KAIROMONES MARKET SIZE, BY PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL KAIROMONES MARKET SIZE, BY PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL KAIROMONES MARKET SIZE, BY VOLATILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL KAIROMONES MARKET SIZE, BY VOLATILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL KAIROMONES MARKET SIZE, BY VOLATILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL KAIROMONES MARKET SIZE, BY NITROGEN VOLATILES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL KAIROMONES MARKET SIZE, BY NITROGEN VOLATILES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL KAIROMONES MARKET SIZE, BY NITROGEN VOLATILES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL KAIROMONES MARKET SIZE, BY SULFUR VOLATILES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL KAIROMONES MARKET SIZE, BY SULFUR VOLATILES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL KAIROMONES MARKET SIZE, BY SULFUR VOLATILES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL KAIROMONES MARKET SIZE, BY NATURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL KAIROMONES MARKET SIZE, BY NATURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL KAIROMONES MARKET SIZE, BY NATURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL KAIROMONES MARKET SIZE, BY ANIMAL DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL KAIROMONES MARKET SIZE, BY ANIMAL DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL KAIROMONES MARKET SIZE, BY ANIMAL DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL KAIROMONES MARKET SIZE, BY MICROBIAL DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL KAIROMONES MARKET SIZE, BY MICROBIAL DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL KAIROMONES MARKET SIZE, BY MICROBIAL DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL KAIROMONES MARKET SIZE, BY PLANT DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL KAIROMONES MARKET SIZE, BY PLANT DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL KAIROMONES MARKET SIZE, BY PLANT DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL KAIROMONES MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL KAIROMONES MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL KAIROMONES MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL KAIROMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL KAIROMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL KAIROMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL KAIROMONES MARKET SIZE, BY GAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL KAIROMONES MARKET SIZE, BY GAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL KAIROMONES MARKET SIZE, BY GAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL KAIROMONES MARKET SIZE, BY AEROSOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL KAIROMONES MARKET SIZE, BY AEROSOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL KAIROMONES MARKET SIZE, BY AEROSOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL KAIROMONES MARKET SIZE, BY VAPOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL KAIROMONES MARKET SIZE, BY VAPOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL KAIROMONES MARKET SIZE, BY VAPOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL KAIROMONES MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL KAIROMONES MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL KAIROMONES MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL KAIROMONES MARKET SIZE, BY EMULSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL KAIROMONES MARKET SIZE, BY EMULSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL KAIROMONES MARKET SIZE, BY EMULSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL KAIROMONES MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL KAIROMONES MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL KAIROMONES MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL KAIROMONES MARKET SIZE, BY SOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL KAIROMONES MARKET SIZE, BY SOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL KAIROMONES MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL KAIROMONES MARKET SIZE, BY GRANULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL KAIROMONES MARKET SIZE, BY GRANULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL KAIROMONES MARKET SIZE, BY GRANULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL KAIROMONES MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL KAIROMONES MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL KAIROMONES MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL KAIROMONES MARKET SIZE, BY ANIMAL BEHAVIOR RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL KAIROMONES MARKET SIZE, BY ANIMAL BEHAVIOR RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL KAIROMONES MARKET SIZE, BY ANIMAL BEHAVIOR RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL KAIROMONES MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL KAIROMONES MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL KAIROMONES MARKET SIZE, BY ENVIRONMENTAL MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL KAIROMONES MARKET SIZE, BY PEST CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL KAIROMONES MARKET SIZE, BY PEST CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL KAIROMONES MARKET SIZE, BY PEST CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL KAIROMONES MARKET SIZE, BY CROP PROTECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL KAIROMONES MARKET SIZE, BY CROP PROTECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL KAIROMONES MARKET SIZE, BY CROP PROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL KAIROMONES MARKET SIZE, BY URBAN PEST CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL KAIROMONES MARKET SIZE, BY URBAN PEST CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL KAIROMONES MARKET SIZE, BY URBAN PEST CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL KAIROMONES MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL KAIROMONES MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL KAIROMONES MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL KAIROMONES MARKET SIZE, BY PLANT DEFENSE RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL KAIROMONES MARKET SIZE, BY PLANT DEFENSE RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL KAIROMONES MARKET SIZE, BY PLANT DEFENSE RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL KAIROMONES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL KAIROMONES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL KAIROMONES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL KAIROMONES MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL KAIROMONES MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL KAIROMONES MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL KAIROMONES MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL KAIROMONES MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL KAIROMONES MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL KAIROMONES MARKET SIZE, BY CROP PROTECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL KAIROMONES MARKET SIZE, BY CROP PROTECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL KAIROMONES MARKET SIZE, BY CROP PROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL KAIROMONES MARKET SIZE, BY LIVESTOCK MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL KAIROMONES MARKET SIZE, BY LIVESTOCK MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL KAIROMONES MARKET SIZE, BY LIVESTOCK MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL KAIROMONES MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL KAIROMONES MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL KAIROMONES MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL KAIROMONES MARKET SIZE, BY COSMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL KAIROMONES MARKET SIZE, BY COSMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL KAIROMONES MARKET SIZE, BY COSMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL KAIROMONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS KAIROMONES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA KAIROMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA KAIROMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE KAIROMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST KAIROMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA KAIROMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL KAIROMONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN KAIROMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 290. GCC KAIROMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. GCC KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. GCC KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 293. GCC KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 294. GCC KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 295. GCC KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 296. GCC KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 297. GCC KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 298. GCC KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 299. GCC KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 300. GCC KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 301. GCC KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 302. GCC KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 303. GCC KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. GCC KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 305. GCC KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 306. GCC KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION KAIROMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPEAN UNION KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 320. EUROPEAN UNION KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 322. EUROPEAN UNION KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS KAIROMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 333. BRICS KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 334. BRICS KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 335. BRICS KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 336. BRICS KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 337. BRICS KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 338. BRICS KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 339. BRICS KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 340. BRICS KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 341. G7 KAIROMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 342. G7 KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. G7 KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 344. G7 KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 345. G7 KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 346. G7 KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 347. G7 KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 348. G7 KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 349. G7 KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 350. G7 KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 351. G7 KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 352. G7 KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 353. G7 KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 354. G7 KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 355. G7 KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 356. G7 KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 357. G7 KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 358. NATO KAIROMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 359. NATO KAIROMONES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 360. NATO KAIROMONES MARKET SIZE, BY NON VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 361. NATO KAIROMONES MARKET SIZE, BY VOLATILE, 2018-2032 (USD MILLION)
  • TABLE 362. NATO KAIROMONES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 363. NATO KAIROMONES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 364. NATO KAIROMONES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 365. NATO KAIROMONES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 366. NATO KAIROMONES MARKET SIZE, BY GAS, 2018-2032 (USD MILLION)
  • TABLE 367. NATO KAIROMONES MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 368. NATO KAIROMONES MARKET SIZE, BY SOLID, 2018-2032 (USD MILLION)
  • TABLE 369. NATO KAIROMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 370. NATO KAIROMONES MARKET SIZE, BY PEST CONTROL, 2018-2032 (USD MILLION)
  • TABLE 371. NATO KAIROMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 372. NATO KAIROMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 373. NATO KAIROMONES MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 374. NATO KAIROMONES MARKET SIZE, BY BIOTECHNOLOGY & PHARMA, 2018-2032 (USD MILLION)
  • TABLE 375. GLOBAL KAIROMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 376. UNITED STATES KAIROMONES MARKET SIZE, 2018